Abstract:Hematological toxicity (hematotoxicity) is the most common long-term
adverse effect following the use of CD19-chimeric antigen receptor
(CD19-CAR) T-cell therapies. However, its management remains unclear. We
present the case of a 21-year-old who received CD19-CAR T-cell therapy
for relapse following a haploidentical transplant. He developed
hematotoxicity and consequently multiple life-threatening infections. We
administered a CD34+ hematopoietic stem cell boost (HSCB) from his
transplant donor that led to he… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.